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Abstract: 
Severe acute respiratory syndrome–coronavirus-2 (SARS-CoV-2) enters cells using the angiotensin 
converting enzyme 2 (ACE2), which are expressed by the respiratory tract endothelium, epithelial cells 
of the stomach, duodenum, ileum, rectum, cholangiocytes, and hepatocytes. Pathological examinations 
of these organs are not feasible method of diagnosis but can explain pathological changes, pathogenesis 
of the disease, and the cause of death in COVID-19 cases. In this review, we performed a literature 
search for COVID-19-related pathological changes seen during post-mortem examinations in different 
organs of the body including the lungs, gastrointestinal tract, liver, kidney, skin, heart and blood. Our 
findings showed that SARS-CoV-2 has damaging effects on many organs, probably due to the host 
immune responses to the presence of the virus. It is recommended that both antiviral and 
immunomodulatory agents should be considered in the management of COVID-19 patients for better 
prognosis, and clinical outcome.  
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Abstrait: 
Le syndrome respiratoire aigu sévère-coronavirus-2 (SARS-CoV-2) pénètre dans les cellules à l'aide de l'enzyme de 
conversion de l'angiotensine 2 (ACE2), qui est exprimée par l'endothélium des voies respiratoires, les cellules 
épithéliales de l'estomac, du duodénum, de l'iléon, du rectum, des cholangiocytes, et les hépatocytes. Les examens 
pathologiques de ces organes ne sont pas une méthode de diagnostic réalisable, mais peuvent expliquer les 
changements pathologiques, la pathogenèse de la maladie et la cause du décès dans les cas de COVID-19. Dans cette 
revue, nous avons effectué une recherche bibliographique sur les changements pathologiques liés au COVID-19 




observés lors d'examens post-mortem dans différents organes du corps, notamment les poumons, le tractus gastro-
intestinal, le foie, les reins, la peau, le cœur et le sang. Nos résultats ont montré que le SRAS-CoV-2 a des effets 
néfastes sur de nombreux organes, probablement en raison des réponses immunitaires de l'hôte à la présence du 
virus. Il est recommandé que les agents antiviraux et immunomodulateurs soient pris en compte dans la prise en 
charge des patients COVID-19 pour un meilleur pronostic et des résultats cliniques. 
Mots-clés: COVID-19, SARS-CoV-2, ACE-2, pathologie, résultats d'autopsie
Introduction:  
 In December 2019 an outbreak of a 
novel coronavirus disease was reported and 
subsequently declared a global pandemic (1). 
The World Health Organization (WHO) officially 
named the disease caused by the severe acute 
respiratory syndrome coronavirus - 2 (SARS-
CoV-2) as coronavirus disease 2019 (COVID-19) 
(2). SARS-CoV-2 is an enveloped, positive- 
sense, single-stranded RNA virus belonging to 
the beta coronavirus family and is the seventh 
coronavirus that cause human infections (3). 
Among the other six coronaviruses that can 
cause diseases in humans are SARS-CoV and 
Middle East respiratory syndrome coronavirus 
(MERS-CoV), which is associated with high mor- 
tality (4,5). SARS-CoV-2 is highly homologous 
to SARS-CoV and enters the cell via the angio- 
tensin converting enzyme 2 (ACE-2).  
 COVID-19 notably present with symp- 
toms of fever, dry cough, fatigue, muscle aches, 
shortness of breath, headache, diarrhea, and 
indigestion (6). It has been observed that from 
the onset of symptoms to death from the 
disease is between 6 and 41 days, and the 
average is 14 days (7). The aim of this review 
was to examine changes in various organs 
including the skin following infection by SARS-
CoV-2. It is hoped that adequate knowledge of 
the pathology of the disease will aid early diag- 
nosis and management of COVID-19, which can 
lead to reduction in mortality and length of 
hospital stay for the patients. 
Methodology: 
 Online databases including the Web of 
Science, PubMed, Scopus, and Google Scholar 
were searched for relevant publications on the 
clinical features, pathogenesis, organ changes 
and complications in COVID-19 following the 
PRISMA guideline (8). We searched for patholo- 
gical changes in terms of gross and microscopic 
morphology on autopsy, immuno-histochemi- 
stry, electron microscopy, fluorescence in-situ 
hybridization (FISH) and RT-PCR used to con- 
firm SARS-COV-2 in these organs or tissues. 
 Search terms and phrases used include; 
“COVID-19 pathology”, “COVID-19 autopsy fin- 
dings”, “COVID-19 diagnostic methods”, “angio- 
tensin-converting enzyme 2 (ACE2)”, “SARS-
CoV-2”, “COVID-19”, “2019-nCoV” and “organ 
changes in COVID-19”. There was no restriction 
on the date, place, type of study, and inclusion/ 
exclusion criteria but publications not written in 
English were excluded. With greatest sensitivity 
search, we found 382 articles on external data- 
bases collected using Endnote Software. All the 
articles from the cited databases were then 
unified to avoid duplicates. Following review of 
the titles and abstracts, non-relevant articles 
were excluded, leaving a total of 60 eligible 
articles for the review (Fig 1). 
Results and Discussion: 
COVID-19 and the lungs  
 The lungs are the most affected organ in 
COVID-19 (9). However, severity of its involve- 
ment ranges from lack of symptoms or mild 
pneumonia to severe hypoxia, shock, respira- 
tory failure, and multiorgan failure or death is 
associated with critical form of the disease (10). 
Grossly the lungs are heavy, often 3-5 times the 
normal size with evidence of congestion and 
haemorrhagic necrosis (11). In over 80% of 
cases, microscopic examination revealed var- 
ious stages of diffuse alveolar damage, including 
the exudative phase with hyaline membrane 
formation, the proliferative phase with type 2 
pneumocyte hyperplasia, and the early repair 
phase with interstitial spindle cell hyperplasia 
and/or intra-alveolar organization (12). 
 Other methods have been used to 
detect SARS-CoV-2 in the lung tissues including 
electron microscopy, immunohistochemistry to 
detect viral antigens, immunofluorescence viral 
nucleic acid detection by in-situ hybridization 
(FISH), and reverse transcriptase polymerase 
chain reaction (RT-PCR) (13). Effort has been 
made to detect SARS-CoV-2 on electron micro- 
scopy which reported “virus-like particles” (14).
  





 In another study, it was reported that 
detection of SARS-CoV-2 by immuno-histo- 
chemistry was successful only in the lung, while 
no virus could be detected by this method in the 
heart, liver, kidney, small intestine, skin, adi- 
pose tissue, and bone marrow (15). Compared 
to immunohistochemistry, immunofluorescence 
has been used less frequently for the detection 
of SARS-CoV-2 proteins/antigens (16), and this 
could partly be due to stronger autofluorescence 
as a cofounding factor and potential infectivity 
of frozen tissues. 
COVID-19 and the heart 
 Clinical features in COVID-19 patients 
suggest that SARS-CoV-2 has a major impact on 
the heart. Patients have features which suggest 
acute myocardial injury, including consistently 
elevated serum troponin level and ECG changes 
(17). The pathophysiology and the degree of 
myocardial injury, along with the short and long-
term cardiovascular outcomes in COVID-19 sur- 
vivors remain unclear. However, autopsy stu- 
dies of the heart in these patients suggest that 
pre-existing heart diseases were dominant, par- 
ticularly hypertensive heart disease (18). In 
other post-mortem studies, the findings showed 
endothelitis, as well as myocardial infiltration 
with lymphocytes, while direct injury of cardio- 
myocytes by the virus was not confirmed (19-
21)      
 One autopsy case series study revealed 
severe right ventricular dilatation in patients, 
along with drop out myocyte necrosis and apop- 
tosis. However there was no evidence of lymp- 
hocytic myocarditis suggesting that elevated 
troponin levels in these patients was due to 
extreme stress from acute pulmonary disease 
(22). Viruses with particular tropism for heart 
directly gain entrance to cardiomyocytes to 
cause their degeneration or to infect endothelial 
cells. These often lead to significant endothelial 
dysfunction, ischemia, cytokine release, and 
infiltration of myocardial tissue with immune 
cells (23). Consequently, innate and adaptive 
immune systems are activated, both being resp- 
onsible for cytokine storm syndrome, as well as 
viral clearance.     
 Left ventricular systolic function impair- 
ment and cardiomyocytes dysfunction often lead 
to death (23). Of particular interest is the report 
of severe myocarditis and decreased systolic 
function after SARS-COV-2 infection, leaving us 
to wonder if the virus induces new cardiac path- 
ologies or merely exacerbates underlying patho- 
logies. It is obvious that as more studies are 
conducted and the disease evolves, more will be 
known about the long term effect of this virus 
on the heart (24). 
COVID 19 and the kidney  
 Although, the first organs to be affected 
in SARS-COV-2 infection are the lungs, as initial  
clinical sign for the detection of COVID-19 is 




pneumonia (25), many organ damages have 
been reported (6) and some cases of COVID-19 
pneumonia present with kidney injury (26). 
Autopsy findings from patients who died of 
COVID-19 also revealed renal damage (27). 
Many studies have reported that SARS-CoV and 
SARS-CoV-2 use the ACE-2 to enter into target 
cells (28), and  ACE-2 is well expressed on the 
surface of kidney tubular cells, which explains 
SARS-CoV-2 tropism for the kidney. 
 Many studies recognized  the relevance 
of the inflammatory/immune-mediated reaction 
with the release of high levels of circulating 
harmful mediators such as IL-1, IL-6, TNF-α and 
chemokines capable of interacting with kidney-
resident cells to cause endothelial dysfunction, 
microcirculatory derangement, and tubular inj- 
ury (29). Acute kidney injury (AKI) developed 
on the average 9 days after admission together 
with secondary infections and acute cardiac 
damage (30). Many factors such as age, severity 
of illness, and the presence of diabetes mellitus 
contribute to AKI in patients with acute respira- 
tory diseases (ARDS) (31).             
 The immune system responses to SARS-
CoV-2 and direct cytotropic effect of the virus 
may be responsible for AKI in COVID-19 (32). 
Studies have shown that severe COVID-19 
patients have reduced levels of CD4+ (helper) 
and CD8+ (cytotoxic) T lymphocytes, NK cells, 
and high levels of inflammatory cytokines. As 
soon as SARS-CoV-2 infiltrates into the renal 
cells, innate immune system and inflammatory 
responses might be triggered causing a cytokine 
storm syndrome, which is responsible for hyp- 
oxia, shock, rhabdomyolysis and acute kidney 
injury (33,34). 
COVID 19 and gastrointestinal system   
 Similar to abundant expression of ACE-
2 in the lungs, it has also been demonstrated on 
the epithelial cells of the stomach, duodenum, 
ileum, rectum, cholangiocytes, hepatocytes of 
the liver and esophageal mucosa (35). From 
physiological point of view, the kidney and the 
gut share a strong association or synergy during 
the maintenance of internal milieu known as the 
gut-kidney axis, which is further divided into 
metabolism-dependent and immune pathways 
(34). Gastrointestinal symptoms such as vomi- 
ting, diarrhea, loss of appetite and abdominal 
pain have been reported in SARS-CoV and 
COVID‐19 patients (36-38).  
 Post-mortem changes in the gastro- 
intestinal linings include vasculitis and increased 
inflammatory infiltrates. The spleen demonst- 
rates increased neutrophil numbers, while the 
mesenteric lymph nodes show increased plamo- 
blasts and congestion (39). 
COVID-19 and the liver  
 Angiotensin converting enzyme-2 (ACE-
2) is abundantly expressed in both the gastro- 
intestinal epithelial cells and the liver, which 
explains a potential direct damage by SARS-
CoV-2 on the liver (40). The liver enzymes, 
alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) levels, are elevated in 
COVID-19 patients, which indicate liver injury in 
these patients. AST elevation is more common 
than ALT, reflecting the contribution of AST from 
sources outside the liver. Hypoalbuminemia and 
slight increase in total bilirubin have been repor- 
ted from several studies (41). Abnormal liver 
biochemistries are uncommon in children (42). 
Many drugs used in the treatment of COVID-19, 
such as antipyretic analgesics, antivirals, anti- 
biotics and glucocorticoids, might have potential 
to cause drug-induced liver injury (43).   
 Autopsy findings from the first case of 
COVID-19 patient revealed that the liver tissue 
showed mild active inflammatory lesions in the 
hepatic lobular portal area, which suggest liver 
injury (44). In vitro studies have shown that 
SARS-CoV can cause direct liver injury (45). 
There is expression of moderate microvascular 
steatosis and mild lobular and portal activity, 
which indicate that liver injury could be caused 
by either SARS-CoV-2 infection or drug-induced 
liver injury (44). 
COVID-19 and the skin 
 Viral illnesses are mostly associated 
with cutaneous manifestations, and may have 
diagnostic or prognostic value. With COVID-19, 
cutaneous manifestations range from rashes to 
eruptions.  
Morbilliform rash     
 This is commonly seen with viral exan- 
themas. Studies from Italy reported that 78% of 
patients with COVID-19 had an erythematous/ 
morbilliform eruption (46).  
Urticaria     
 A study from France reported that a 
patient developed an urticarial eruption along 
with odynophagia and diffuse arthralgia 48 hrs 
before onset of fever, chills and COVID-19 diag- 
nosis (47). This unusual presentation of urticaria 
before the more well-known symptoms, signals 
the possibility that cutaneous eruptions can be 
a presenting symptom of COVID-19.  
 




Vesicular eruptions   
 These resembles herpes vesicular erup- 
tions and have been reported in COVID-19 
patients (48). It was also observed that the 
median latency time from COVID-19 systemic 
symptoms to the rash was 3 days, and the 
median duration of skin manifestations was 8 
days (49).  
COVID toes    
 Research on cutaneous manifestations 
of coronavirus disease 2019 (COVID-19) are still 
going on. Acral cutaneous lesions also known as 
Covid toes have been reported in patients with 
COVID-19. the pattern of acral lesions is desc- 
ribed as erythematous to purple, purpuric macu- 
les, papules and/or vesicles (50).  
Livedoid eruptions    
 Many cases of Livedo reticularis-like 
eruptions have been reported in US patients 
with COVID-19 (51). It has been hypothesized 
that SARS‐CoV‐2 induces immune complexes 
formation with inflammation and vasculitis.  This 
was further demonstrated on skin biopsies 
which showed small vessel thrombosis with no 
viral skin identification (52), demonstrating the 
possibility that tissue abnormalities are due to 
systemic toxicity triggered by a disproportionate 
immune response, rather than to direct viral 
spread. Another hypothesis is that the virus 
itself causes vascular damage, binding to ACE-
2, which is widely expressed in endothelial cells 
(35). Early recognition of these cutaneous les- 
ions may help to rapidly start treatment, since 
their worsening may be related to a severe syst- 
emic involvement. 
COVID 19 and the neurologic system  
 Despite the fact that SARS-CoV-2 has 
been noted to principally affect the respiratory 
system, many studies have reported the invol-    
vement of neurological system. Neurological 
involvement in COVID-19 has been discussed in 
three sections; first is neurological features of 
viral infection, second is post-infective neurolo- 
gical complications, and third is infection in 
patients with neurological co-morbidity (53). 
Haematogenous spread and retrograde axonal 
transport have been described as routes for 
neuro-invasion by a coronavirus (54). Like other 
viruses, SARS-CoV-2, has been observed to 
directly invade the brain leading to clinical ence- 
phalitis (55). Other heterogeneous mechanisms 
such as cytokine storm and secondary hyper- 
coagulability caused by the virus are thought to 
be involved.   
 Neurological manifestations in SARS-
CoV-2 infection can be grouped into central 
nervous system (CNS) and peripheral nervous 
system (PNS). CNS features include headache, 
dizziness, ataxia, altered sensorium, encepha- 
litis, stroke and seizures, while PNS features are 
seen as skeletal muscle injury and peripheral 
nerve involvement in the form of hyposmia and 
hypogeusia.     
 Post infective neurological complications 
including demyelinating conditions were prev- 
iously reported (56). Guillain-Barré syndrome 
(GBS) is an inflammatory polyradiculoneuro- 
pathy associated with numerous viral infections. 
Recently, there have been many case reports 
describing the association between COVID-19 
and GBS. However, despite numerous case 
reports of GBS associated with COVID-19, the 
prevalence remains unclear (57). In most of the 
cases reported, the patients were over 50 years 
of age, with male predominance (58). Corona- 
virus infection of the CNS has long provided a 
model for studying demyelinating diseases such 
as multiple sclerosis, vaccine design, and novel 
immunotherapeutic to limit virus spread (59). 
Even though the neurological manifestations in 
the majority of infected patients are mild, mana- 
gement of these patients should be a multi- 
disciplinary approach.   
 The post-mortem nuclear magnetic res- 
onance (NMR) findings of COVID-19 patients 
were parenchymal brain abnormalities such as 
subcortical macrobleeds and microbleeds, and 
edematous changes, which were suggestive of           
posterior reversible encephalopathy syndrome 
(PRES), and non-specific changes in the white 
matter (60).  
Conclusion: 
 SARS-CoV-2 directly damage the lungs, 
heart, kidneys, liver, skin and brain. However, 
most of the injuries to these organs is caused by 
abnormal host immune responses to the virus. 
In the management of COVID-19 patients, it is 
recommended that both antiviral and immuno- 
modulatory agents be applied for better prog-
nosis and disease outcome. 
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